Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modulated Electro-hyperthermia in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT05889390Phase 3Active, not recruiting
- Sponsor
- Semmelweis University
- Start
- Feb 2023
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms), sponsored by Semmelweis University. Primary endpoint: Residual size of the primary tumor at 6 months. Started Feb 2023; status: active, not recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05889390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05889390.